{"id":"drv-cobi-fdc","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1323","moleculeType":"Small molecule","molecularWeight":"547.67"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darunavir binds to and inhibits HIV protease, preventing the cleavage of viral polyproteins necessary for infectious particle maturation. Cobicistat is a cytochrome P450 inhibitor that boosts darunavir plasma concentrations by inhibiting its metabolism, allowing for lower and less frequent dosing while maintaining therapeutic levels. Together, they reduce viral load in HIV-infected patients.","oneSentence":"DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:01.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT03123848","phase":"PHASE4","title":"A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-04-14","conditions":"Healthy","enrollment":8},{"nctId":"NCT03227861","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2017-07-31","conditions":"HIV-1","enrollment":109},{"nctId":"NCT02578550","phase":"PHASE1","title":"A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-11","conditions":"Healthy","enrollment":126},{"nctId":"NCT04718805","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-26","conditions":"Healthy","enrollment":22},{"nctId":"NCT04661397","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-05","conditions":"Healthy","enrollment":37},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT05197075","phase":"PHASE1","title":"A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-03","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":15},{"nctId":"NCT05378906","phase":"PHASE1","title":"A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT02431247","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-07-06","conditions":"Immunodeficiency Virus Type 1, Human","enrollment":725},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02993237","phase":"PHASE1","title":"Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-23","conditions":"HIV-1","enrollment":27},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02475135","phase":"PHASE1","title":"Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-06-01","conditions":"Healthy","enrollment":72},{"nctId":"NCT01565850","phase":"PHASE2","title":"D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-04","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TMC114/JNJ-48763364"],"phase":"phase_3","status":"active","brandName":"DRV/COBI FDC","genericName":"DRV/COBI FDC","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-naive and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}